Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 14 Brain Neoplasms 12 Glioma 11 Astrocytoma 9 Meningioma 7 Central Nervous System Neoplasms 7 Gliosarcoma 6 Diffuse Intrinsic Pontine Glioma 6 Recurrence 4 Neurofibromatosis 2 4 Tuberous Sclerosis 3 Pheochromocytoma 3 Paraganglioma 3 Neuroma, Acoustic 3 Rhabdomyosarcoma 2 Oligodendroglioma 2 Neurofibromatosis 1 2 Neuroendocrine Tumors 2 Neoplasms 2 Hereditary Sensory and Autonomic Neuropathies 2 von Hippel-Lindau Disease 1 Zollinger-Ellison Syndrome 1 Vestibulocochlear Nerve Diseases 1 Tuberous Sclerosis 2 1 Tongue Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Somatostatinoma 1 Seizures 1 Sarcoma 1 Salivary Gland Neoplasms 1

Interventions

mirdametinib 2 tipifarnib 1 talimogene laherparepvec 1 peginterferon alfa-2b 1 nilotinib 1 binimetinib 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Vincristine 1 Temozolomide 1 Talaporfin 1 Sirolimus 1 Restraint, Physical 1 Ranibizumab 1 Radiosurgery 1 Photochemotherapy 1 Neurofibromin 1 1 Mn-PyC3A 1 Imatinib Mesylate 1 Everolimus 1 Elasticity Imaging Techniques 1 Deoxycholic Acid 1 Cryotherapy 1 Celecoxib 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibroma × Everolimus × CNS × Clear all

NCT02332902 2023-12-20

DCLNF1

The University of Texas Health Science Center, Houston

Phase 2 Completed

24 enrolled 4 charts

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡